GEM-X, the next generation of the company's
leading single cell technology architecture, enables higher
performance at larger scale and lower cost
Pre-orders now open for first two Chromium
products powered by GEM-X; expected to ship in Q1
PLEASANTON, Calif., Feb. 7, 2024
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in
single cell and spatial biology, announced today the launch of
GEM-X, the next generation of the company's leading single cell
technology. The first major overhaul to the Chromium architecture
since the 2019 launch of Next GEM technology, GEM-X is built on a
new and improved microfluidic chip design, featuring the latest
technological advancements and optimized reagents for superior
performance and high reliability.
"With GEM-X, we are advancing our leadership in single cell
analysis, raising the bar on performance and setting a new standard
for the field," said Michael
Schnall-Levin, Founding Scientist and Chief Technology
Officer of 10x Genomics. "This is a game-changing technology that
will help drive better, faster and more cost effective single cell
research and enable more academic and translational researchers to
routinely rely on these tools to help resolve biology's
complexity."
The company is now accepting preorders for the first two product
launches powered by the GEM-X technology architecture, Chromium
Single Cell Gene Expression 3'v4 and Chromium Single Cell Immune
Profiling 5'v3. These assays are expected to begin shipping this
quarter.
The new GEM-X technology offers significant performance
advantages, including:
- Substantially increased sensitivity: Detect up to two
times more genes compared to on-market Chromium assays to gain a
more comprehensive view of cellular heterogeneity
- Built to scale: Two-fold increase in cells captured per
channel
- More cost effective: More than two-fold reduction in
cost per cell
- Enhanced data quality: Two-fold reduction in multiplet
rate enabling high quality data at scale
- Maximum sample recovery: Recovery of up to 80% of cells,
improving capture efficiency and making it ideal for samples
typically yielding few cells, such as tissue biopsies or previously
flow sorted cells
- Improved assay robustness: Redesigned microfluidics and
optimized reagents for faster and more efficient cell
partitioning
"This is just the beginning for GEM-X and for single cell
analysis," added Schnall-Levin. "We have a robust GEM-X roadmap
ahead, including a comprehensive menu of high performance assays
and applications with the economics to drive broad adoption and
large scale."
GEM-X is exclusively available for use on Chromium X Series
instruments.
About 10x Genomics
10x Genomics is a life science
technology company building products to accelerate the mastery of
biology and advance human health. Our integrated solutions include
instruments, consumables and software for single cell and spatial
biology, which help academic and translational researchers and
biopharmaceutical companies understand biological systems at a
resolution and scale that matches the complexity of biology. Our
products are behind breakthroughs in oncology, immunology,
neuroscience and more, fueling powerful discoveries that are
transforming the world's understanding of health and disease. To
learn more, visit 10xgenomics.com or connect with us on
LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding 10x
Genomics, Inc.'s ("10x Genomics") product launches, performance,
configuration, costs, capabilities, adoption and pipeline. These
statements are based on management's current expectations,
forecasts, beliefs, assumptions and information currently available
to management, and actual outcomes and results could differ
materially from these statements due to a number of factors. Other
risks and uncertainties that could affect 10x Genomics' financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics files with the Securities and Exchange Commission (the
"SEC") from time to time. Although 10x Genomics believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to 10x Genomics as of
the date hereof, and 10x Genomics disclaims any obligation to
update any forward-looking statements provided to reflect any
change in its expectations or any change in events, conditions or
circumstances on which any such statement is based, except as
required by law. These forward-looking statements should not be
relied upon as representing 10x Genomics' views as of any date
subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-expands-leadership-in-single-cell-analysis-with-launch-of-gem-x-technology-302056515.html
SOURCE 10x Genomics, Inc